Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jihad Inshasi

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Postgraduate Medicine|February 25, 2020
Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activityRaed Alroughani, Jihad Inshasi, Abdullah Al-Asmi, et al.
The International Journal of Neuroscience|April 9, 2010
Adherence to disease-modifying drugs in patients with multiple sclerosis: a consensus statement from the Middle East MS Advisory GroupBassem I Yamout, Maurice Dahdaleh, Mohammed Ali Al Jumah, et al.
The International Journal of Neuroscience|December 29, 2016
Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet?Maurice Dahdaleh, Raed Alroughani, Mohammed Aljumah, et al.
Scientific Reports|November 21, 2019
CT pattern of Infarct location and not infarct volume determines outcome after decompressive hemicraniectomy for Malignant Middle Cerebral Artery StrokeSaadat Kamran, Naveed Akhtar, Abdul Salam, et al.
Therapeutic Advances in Neurological Disorders|September 25, 2020
The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspectiveRaed Alroughani, Bart Van Wijmeersch, Jabber Al Khaboori, et al.
Neurology and Therapy|June 8, 2023
Multicentre Observational Study of Treatment Satisfaction with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in the Arabian Gulf: The CLUE StudyJihad Inshasi, Samar Farouk, Ahmed Shatila, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 14, 2022
Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: An expert consensus narrative reviewRaed Alroughani, Jihad Inshasi, Mona Al Khawajah, et al.
Therapeutic Advances in Neurological Disorders|April 30, 2025
Cost-effectiveness of ofatumumab for the treatment of relapsing forms of multiple sclerosis in the United Arab EmiratesJihad Inshasi, Yomna Nowier, Evelina A Zimovetz, et al.
Journal of the Neurological Sciences|September 30, 2010
Risk factors, management and outcome of subtypes of ischemic stroke: a stroke registry from the Arabian GulfDirk Deleu, Jihad Inshasi, Naveed Akhtar, et al.
Clinical Neurology and Neurosurgery|March 14, 2021
Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA)Raed Alroughani, Zuhair AlKawi, Ahmed Hassan, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Postgraduate Medicine|February 25, 2020
Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activityRaed Alroughani, Jihad Inshasi, Abdullah Al-Asmi, et al.
The International Journal of Neuroscience|April 9, 2010
Adherence to disease-modifying drugs in patients with multiple sclerosis: a consensus statement from the Middle East MS Advisory GroupBassem I Yamout, Maurice Dahdaleh, Mohammed Ali Al Jumah, et al.
The International Journal of Neuroscience|December 29, 2016
Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet?Maurice Dahdaleh, Raed Alroughani, Mohammed Aljumah, et al.
Scientific Reports|November 21, 2019
CT pattern of Infarct location and not infarct volume determines outcome after decompressive hemicraniectomy for Malignant Middle Cerebral Artery StrokeSaadat Kamran, Naveed Akhtar, Abdul Salam, et al.
Therapeutic Advances in Neurological Disorders|September 25, 2020
The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspectiveRaed Alroughani, Bart Van Wijmeersch, Jabber Al Khaboori, et al.
Neurology and Therapy|June 8, 2023
Multicentre Observational Study of Treatment Satisfaction with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in the Arabian Gulf: The CLUE StudyJihad Inshasi, Samar Farouk, Ahmed Shatila, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|March 14, 2022
Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: An expert consensus narrative reviewRaed Alroughani, Jihad Inshasi, Mona Al Khawajah, et al.
Therapeutic Advances in Neurological Disorders|April 30, 2025
Cost-effectiveness of ofatumumab for the treatment of relapsing forms of multiple sclerosis in the United Arab EmiratesJihad Inshasi, Yomna Nowier, Evelina A Zimovetz, et al.
Journal of the Neurological Sciences|September 30, 2010
Risk factors, management and outcome of subtypes of ischemic stroke: a stroke registry from the Arabian GulfDirk Deleu, Jihad Inshasi, Naveed Akhtar, et al.
Clinical Neurology and Neurosurgery|March 14, 2021
Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA)Raed Alroughani, Zuhair AlKawi, Ahmed Hassan, et al.
Pageof 5